FSH Blood Test: Normal Ranges & Causes | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

FSH blood test

Follicle-stimulating hormone. Also called: Follitropin, Follicle stimulating hormone

Biomarker guideLast updated: October 30, 2026

FSH is the pituitary hormone that drives egg follicles in the ovaries and sperm production in the testes. It rises sharply when the ovaries or testes fail, which makes it a marker of menopause and of primary testicular failure.

LOINC 15067-2HormonesSexual

At a glance

What it measuresFollicle-stimulating hormone, a pituitary gonadotropin that drives follicle growth and sperm production.
SampleBlood (serum or plasma). In women, note the cycle day; FSH comes in pulses.
Typical adult rangeMen: 1.5-12.4 (Labcorp), 1.4-12.8 mIU/mL (Quest). Postmenopausal women: 25.8-134.8 (Labcorp), 23.0-116.3 (Quest).
Common reasons it reads highMenopause and the menopausal transition, primary ovarian insufficiency, primary testicular failure (including Klinefelter syndrome), castration and alcoholism.
Peptides that move itRaised by Kisspeptin-10 (in men) and HMG (Human Menopausal Gonadotropin). Suppressed by Leuprolide, Triptorelin, Goserelin and Nafarelin after an initial surge, and by Degarelix and Ganirelix. No significant change on Human Chorionic Gonadotropin (hCG).
Lab codeLOINC 15067-2 (Labcorp 004309, Quest 470)

What is FSH?

Follicle-stimulating hormone (FSH) is a glycoprotein from the pituitary gland, a member of the gonadotropin family with LH. In the ovaries it stimulates follicle growth, and in men it acts on the Sertoli cells that support sperm production.

Labcorp uses FSH with LH to tell primary gonadal failure from pituitary or hypothalamic causes, to define the phases of the menstrual cycle in fertility work-ups, and to assess testicular function in men.

Sources: [1] [2]

How it is made and regulated

Where it is made

Gonadotropin-releasing hormone (GnRH) from the hypothalamus stimulates the pituitary to release both FSH and LH. FSH is a two-subunit glycoprotein with a molecular weight of about 32,000.

Sources: [3] [1]

What controls it

FSH and LH are released in pulses, and circulating levels are controlled by sex steroids through negative feedback to the hypothalamus. FSH bursts and LH bursts coincide only partly, suggesting partly separate control.

Sources: [1] [4]

How it travels in the blood

In men, FSH acts on Sertoli cells to support spermatogenesis, working together with testosterone.

Sources: [2]

How long it lasts

We found no reliable half-life figure for FSH in the sources reviewed for this page. What matters for testing is its pulsatile release and, in women, the cycle phase.

Sources: [1]

What it does

As the number of ovarian follicles dwindles in the menopausal transition, FSH rises in a state of "compensated failure" before the ovary finally stops producing functioning follicles.

Sources: [5]

Reference ranges

FSH ranges depend on sex, age and, in women, the cycle phase. After menopause FSH is several times the premenopausal range.

Labcorp (test 004309)

Method: Electrochemiluminescence immunoassay (ECLIA). Labcorp test page (retrieved October 30, 2026).

GroupRange (mIU/mL)
Adult men1.5-12.4
Adult women, follicular phase3.5-12.5
Adult women, ovulatory phase4.7-21.5
Adult women, luteal phase1.7-7.7
Adult women, postmenopausal25.8-134.8
Children and teens
GroupRange (mIU/mL)
Boys, 10 to 12 years0.4-4.6
Girls, 10 to 12 years2.1-11.1
Boys, 13 to 16 years1.5-12.9
Girls, 13 to 16 years1.6-17.0

Labcorp also lists ranges for newborns and young children on its page.

Quest Diagnostics (test 470)

Method: Immunoassay (IA). Quest Diagnostics test page (retrieved October 30, 2026).

GroupRange (mIU/mL)
Men1.4-12.8
Women, follicular phase2.5-10.2
Women, mid-cycle peak3.1-17.7
Women, luteal phase1.5-9.1
Women, postmenopausal23.0-116.3

Ranges as shown for Quest's East region; not established for pre-pubertal children with this assay.

mIU/mL is the same as IU/L. Quest bases its ranges on people after puberty and recommends a separate pediatric FSH test for younger children. Quest's ranges are for its East region.

Sources: [1] [6]

Is there an "optimal" range?

FSH is widely used as a fertility and menopause test, but it is better at confirming ovarian failure than at predicting fertility.

Lab ranges by cycle phase

Follicular 3.5-12.5; postmenopausal 25.8-134.8 mIU/mL (Labcorp)

Labcorp 004309 and Quest 470

Labs publish phase-specific ranges because FSH varies through the cycle; a single value must be read with the cycle day.

Sources: [1] [6]

Ovarian reserve markers do not predict fertility

American Society for Reproductive Medicine committee opinion (2020)

Ovarian reserve markers, which include hormone levels, help predict how many eggs a stimulation cycle will yield, but they are poor predictors of reproductive potential independent of age.

Sources: [7]

FSH tracks the menopausal transition

Stages of Reproductive Aging Workshop (STRAW 2001, STRAW+10 2012); reviews of the transition

Staging systems for reproductive aging use menstrual pattern and hormone criteria; FSH rises as follicles dwindle, before the final period.

Sources: [8] [9] [5]

What raises it

FactorHowHow much
Menopause and the menopausal transitionPhysiologyAs ovarian follicles run out, falling feedback lets FSH rise.Labcorp postmenopausal range 25.8-134.8 mIU/mL [5] [1]
Primary gonadal failureConditionLabcorp lists hypogonadism, anorchia, gonadal failure, Klinefelter syndrome, menopause, alcoholism and castration as causes of excessive FSH and LH.No published magnitude [1] [10]
Primary ovarian insufficiencyConditionPremature loss of ovarian function raises FSH; a 2024 international guideline gives 145 recommendations on its diagnosis and care.No published magnitude [11]
hMG and kisspeptinPeptidehMG contains FSH; kisspeptin stimulates GnRH in men. See the peptide table below.No published magnitude [12] [13] [14]

What lowers it

FactorHowHow much
Pituitary or hypothalamic diseaseConditionFSH and LH are both low in pituitary or hypothalamic failure; Kallmann syndrome is an inborn GnRH deficiency.No published magnitude [1] [15]
Oral contraceptivesMedicationAll the pills studied suppressed FSH equally early and effectively.No published magnitude [16]
GnRH agonists and antagonistsPeptideAgonists first surge FSH, then suppress it; antagonists suppress it directly. See the peptide table below.Leuprolide: decreased FSH within two to four weeks of continuous dosing [17]

Peptides that affect FSH

How each peptide in our library has been shown to affect FSH, strongest evidence first. GnRH agonists are listed as "lowers", but each first causes a short FSH surge; the size column gives both. hCG did not raise FSH. "No clear effect" means FSH was measured and did not change; "Unclear" means the results conflict.

PeptideEffect on FSHSize of effectEvidence
ExenatideRaisesWomen with PCOS, exenatide vs metformin (sustained, RCT meta-analyses): FSH MD 0.82 [95% 0.41, 1.24]; in a second meta-analysis MD 0.43 (0.02 to 0.84), P = 0.04In women with PCOS, FSH ended slightly higher on exenatide than on metformin in pooled trials. Weight loss is a likely confounder. [18] [19]Human trials
HMG (Human Menopausal Gonadotropin)RaisesSingle dose (2 ampules) in 10 ovulatory women and 10 women with PCOS (acute): serum FSH rose in ovulatory women only (no percentage given for hMG)hMG contains FSH, so measured FSH rose after a dose in women with normal cycles but not in PCOS. [12]Human trials
Kisspeptin-10RaisesHealthy men: FSH rose after IV bolus kisspeptin-10 from 1.0 nmol/kg, and acute SC infusions (1.25-10.0 nmol/kg/h) raised FSH dose-dependently. Women: no change in the follicular phaseKisspeptin-10 raises FSH in men; women in the follicular phase did not respond. [13] [14]Human trials
TirzepatideRaisesMen with obesity and metabolic hypogonadism, tirzepatide 2.5 mg weekly for the first month then 5 mg, plus diet and walking, 2 months (28 men; controls: lifestyle only or testosterone gel), electrochemiluminescence immunoassay: FSH median 1.8 to 3.2 mIU/mL, higher than both control groupsA 2-month pilot in 28 men with obesity and low testosterone, not randomized; FSH rose alongside weight loss. [20]Human trials
BuserelinLowersSame men (600 micrograms intranasally 3 times daily): FSH rose on day 1, then fell by 70 to 80% within 1 to 3 weeks, with partial FSH recovery after the first monthFSH surges first, then falls; it partly recovered after the first month in one study. [21]Human trials
GhrelinLowersSame 6 women, overnight ghrelin vs placebo (acute): FSH AUC 5.54 vs 5.87 mIU/min·ml (P=0.038)Overnight ghrelin injections slightly lowered FSH secretion in a small study of women. [22]Human trials
DulaglutideNo clear effectSame PCOS trial: FSH change -0.56 IU/L with dulaglutide vs +0.26 IU/L with diet alone (p = 0.237)No FSH change in one randomized PCOS trial. [23]Human trials
GalaninNo clear effectAcute: 8 healthy men (90-min human galanin infusion) and 13 ovulatory women (porcine galanin 500 micrograms IV): FSH unchanged in bothGalanin infusions did not change FSH in men or women. [24] [25]Human trials
Human Chorionic Gonadotropin (hCG)No clear effectSame men on hCG 1000-3000 IU twice a week (sustained): FSH 3.1 to 3.05 mIU/mL, no significant changehCG did not change FSH in men on hCG monotherapy, consistent with it acting on the testes rather than the pituitary. [26]Human trials
LanreotideNo clear effectEighteen patients with active acromegaly given somatostatin analogs (octreotide or lanreotide) for 4 weeks before surgery (sustained): no change in LH or FSH; no values in the abstract, and lanreotide was not reported separately from octreotideNo FSH change in a small presurgical acromegaly study that pooled lanreotide with octreotide. [27]Human trials
MacimorelinNo clear effect28 healthy volunteers, single oral dose 0.5 and 0.75 mg/kg (acute), sampled to 120 min: no FSH changeA single diagnostic dose did not change FSH. [28]Human trials
Neuropeptide YNo clear effect6 normal men, single IV bolus of 100 micrograms NPY (acute): no effect alone; the FSH response to LHRH was only slightly (non-significantly) potentiatedNPY did not meaningfully change FSH in men. [29]Human trials
OctreotideNo clear effectNine insulin-dependent diabetic women, 100 micrograms twice daily for 7 days: no significant fall in gonadotropins; eighteen acromegaly patients on octreotide or lanreotide for 4 weeks: no FSH changeSmall studies found no FSH change on octreotide. [30] [27]Human trials
SomatostatinNo clear effectSame acute infusion study in normal menstruating women (5.55 micrograms/min for 180 min): the FSH response to LH-RH was not alteredThe FSH response to a GnRH test was unchanged during a somatostatin infusion. [31]Human trials
Corticotropin-Releasing Hormone (CRH)UnclearHumans, acute IV infusion: FSH unchanged in cycling and postmenopausal women and in agonadal women. Ovariectomized rhesus monkeys, 5-h hCRH infusion (100 micrograms/h): FSH fell 26% to 49% over hours 1-5No FSH change in people; FSH fell in monkeys. [32] [33]Human trials
GonadorelinUnclearSame 5 women, pulsatile gonadorelin: FSH 3.7 to 6.3 U/L after 1 week, not statistically significant (P=0.162)FSH rose on pulsatile gonadorelin but the change was not significant in this very small study. [34]Human trials
SermorelinUnclearAcute single IV dose. 20 short prepubertal children, GHRH 1-29 1 microgram/kg: a short-term, small FSH rise (p < 0.05). No effect on other pituitary hormones when combined with LHRH plus TRHUnclear: a small, short FSH rise after one dose in children, but no change when given with other releasing hormones. [35] [36]Human trials
Thyrotropin-Releasing Hormone (TRH)UnclearTRH infusion 2.0 microgram/min in 10 normal men: FSH about 50% above basal. IV TRH in ovulatory women: FSH rose but not significantly. Oral TRH in postmenopausal women: no FSH changeUnclear: an infusion raised FSH in men, but IV TRH in women and oral TRH in postmenopausal women did not change it significantly. [37] [38] [39]Human trials
DegarelixLowersMen with prostate cancer, single 240 mg dose: FSH falls along with LH, followed by testosteroneFSH falls after the first dose, per the label. [40]FDA label
GanirelixLowersWomen in IVF (daily SC injections, sustained): FSH is suppressed, less than LH; no initial release of gonadotropins detected; FSH recovers within 48 hours of stoppingA GnRH antagonist: FSH falls (less than LH) without a detected initial surge. [41]FDA label
GoserelinLowersImplant 3.6 mg every 28 days (sustained). Initial surge: an initial increase in serum FSH after the first dose (label, men). Suppression: FSH suppressed to follicular phase levels within four weeks (label, women)A GnRH agonist: FSH rises at first, then is suppressed within about four weeks. [42]FDA label
LeuprolideLowersLupron Depot label: an initial increase in circulating FSH (with a transient rise in gonadal steroids), then decreased FSH with continuous administration, occurring within two to four weeks; no FSH values givenA GnRH agonist: FSH first surges, then falls with continued dosing within two to four weeks. [17]FDA label
NafarelinLowersSynarel label: at the onset nafarelin stimulates LH and FSH release; repeated dosing abolishes the stimulatory effect. A review describes the resulting decrease in gonadotropin release; no FSH values givenA GnRH agonist: FSH first rises, then gonadotropin release falls with continued dosing. [43] [44]FDA label
TriptorelinLowersInitial surge: after the first dose "a transient surge in circulating levels of ... follicle-stimulating hormone (FSH)". Suppression: "usually 2 to 4 weeks after initiation of therapy, a sustained decrease in LH and FSH secretion" (Trelstar; Triptodur: by 4 weeks)A GnRH agonist: FSH rises after the first injection, then is suppressed within about 2-4 weeks. [45] [46]FDA label
CetrorelixNo clear effectWomen in controlled ovarian stimulation (0.25 mg doses): FSH not affected; the label notes a more pronounced effect on LH than on FSHAt IVF doses the label reports no FSH effect. [47]FDA label
IrisinRaisesMale Wistar rats (200 ng/kg SC, 30 days) and Kurdish ewes (IV 20-40 ng/kg every three days for 45 days): serum FSH increasedIrisin raised FSH in rats and sheep. No human data. [48] [49]Animal studies
MOTS-cRaises80 male Wistar rats (obese and non-obese), MOTS-c 10 or 100 µM infused into the brain ventricles for 14 days (sustained): serum FSH rose (p < 0.05); no values in the abstractMale rat data with brain infusion only; raised FSH. No human data. [50]Animal studies
AdropinNo clear effectSame rat study (4 or 40 μg/kg/day intraperitoneally for 10 days): FSH did not differ between groupsFSH did not change in one rat study. No human data. [51]Animal studies
BradykininNo clear effectSame rat study (25 micrograms into the third ventricle, acute): plasma FSH no different from salineNo FSH change in a 1980 rat study. No human data. [52]Animal studies
GHRP-2No clear effectConscious swine, acute IV doses of GHRP-2 (specificity study): plasma FSH not affectedIn pigs, GHRP-2 released GH without changing FSH. No human FSH data. [53]Animal studies
GHRP-6No clear effectConscious swine, acute IV doses of GHRP-6 (specificity study): plasma FSH not affectedIn pigs, GHRP-6 released GH without changing FSH. No human FSH data. [53]Animal studies
IpamorelinNo clear effectConscious swine, acute IV doses of Ipamorelin (specificity study): plasma FSH not affectedIn pigs, Ipamorelin released GH without changing FSH. No human FSH data. [53]Animal studies
ObestatinNo clear effectSame peripubertal female sheep (obestatin into the brain ventricles, 3 days): pituitary FSH rose but mean blood FSH was unchangedSheep data only; blood FSH did not change. [54]Animal studies
VasotocinNo clear effectOvariectomized conscious rats, same intraventricular and IV doses (acute): plasma FSH unaffectedRat data only; FSH did not change. [55]Animal studies

What high or low results can mean

A high result

A high FSH means the gonads are failing to respond: menopause, primary ovarian insufficiency, or primary testicular failure in men.

  • Menopause or the menopausal transition
  • Primary ovarian insufficiency
  • Primary testicular failure, including Klinefelter syndrome
  • Castration or anorchia
  • Alcoholism

Next step: Interpret with LH, estradiol or testosterone and the cycle day. Repeat a borderline result, since FSH is pulsatile.

Sources: [1] [5] [11]

A low result

A low or inappropriately normal FSH with low sex hormones points to the pituitary or hypothalamus. Oral contraceptives also suppress FSH.

  • Pituitary or hypothalamic disease
  • Kallmann syndrome
  • Oral contraceptives
  • GnRH agonist or antagonist treatment

Next step: Further pituitary assessment may be needed, depending on the clinical picture. Tell the clinician about the pill or other hormone treatment.

Sources: [1] [15] [16]

How the test works

SampleLabcorp takes serum (preferred) or lithium-heparin plasma, not oxalate, EDTA or citrate plasma.
FastingNeither Labcorp nor Quest lists a fasting requirement for FSH.
TimingIn women, note the cycle day; FSH varies through the cycle. Because FSH and LH are pulsatile, Labcorp notes that pooling samples taken every 15-30 minutes reduces the effect of a single pulse. Stop high-dose biotin at least 72 hours before.
Lab differencesLabcorp uses an ECLIA and Quest an immunoassay. Quest recommends its separate pediatric FSH assay for children before puberty.
RetestingFSH is fairly stable within a person: within-person variation was about 8% in men.
Labcorp order code004309: Follicle-stimulating Hormone (FSH)
Quest Diagnostics order code470: FSH (Follicle Stimulating Hormone)
LOINC codes
  • 15067-2: Follitropin [Units/volume] in Serum or Plasma
LOINC 15067-2 on loinc.org

Sources: [1] [6] [56] [57]

History

FSH was isolated from the pituitary in 1949. The discovery of GnRH in 1971 showed one hypothalamic hormone controls both FSH and LH, and staging systems now use FSH to chart the menopausal transition.

  1. 1949Pituitary follicle-stimulating hormone is isolated. [58]
  2. 1971Gonadotropin-releasing hormone is identified as one peptide that releases both LH and FSH. [3]
  3. 1996FSH is shown to be released in discrete secretory bursts in women, only partly in step with LH. [4]
  4. 2001The Stages of Reproductive Aging Workshop (STRAW) proposes a staging system for female reproductive aging. [9]
  5. 2012STRAW+10 updates the staging criteria for the menopausal transition. [8]
  6. 2020The American Society for Reproductive Medicine states that ovarian reserve markers are poor predictors of reproductive potential independent of age. [7]

FAQ

What is a normal FSH level?

For men, 1.5-12.4 mIU/mL at Labcorp and 1.4-12.8 at Quest. For women it depends on the cycle: Labcorp's follicular range is 3.5-12.5, and postmenopausal 25.8-134.8.

Sources: [1] [6]

Can FSH tell me if I am in menopause?

FSH rises as the ovaries fail and is far higher after menopause (Labcorp 25.8-134.8 mIU/mL). In the transition it fluctuates, so staging systems also use the menstrual pattern.

Sources: [1] [5] [8]

Is FSH a good fertility test?

Not on its own. The American Society for Reproductive Medicine says ovarian reserve markers help predict egg yield with stimulation but are poor predictors of reproductive potential independent of age.

Sources: [7]

What does a high FSH mean in a man?

It points to a problem with sperm production or the testes, such as Klinefelter syndrome or other primary testicular failure. FSH acts on the Sertoli cells that support sperm production.

Sources: [1] [10] [2]

Why is FSH tested with LH?

Both are high when the gonads fail and both are low when the pituitary or hypothalamus fails, so together they locate the problem.

Sources: [1]

Does the pill affect FSH?

Yes. All oral contraceptives studied suppressed FSH equally early and effectively, so FSH on the pill does not reflect ovarian function.

Sources: [16]

Does hCG raise FSH?

No. In men with testosterone above 300 ng/dL taking Human Chorionic Gonadotropin (hCG) twice weekly, FSH went from 3.1 to 3.05 mIU/mL, not a significant change.

Sources: [26]

Does kisspeptin raise FSH?

In men, yes: Kisspeptin-10 raised FSH after an IV bolus and dose-dependently with infusions. In women in the follicular phase there was no change.

Sources: [13] [14]

What do GnRH drugs do to FSH?

Agonists such as Leuprolide first cause an initial increase in FSH, then decrease it within two to four weeks of continuous dosing. Antagonists such as Ganirelix suppress it without the initial release: "An initial release of endogenous gonadotropins has not been detected."

Sources: [17] [41]

Why can one FSH test be misleading?

FSH is released in pulses and, in women, changes through the cycle. Labcorp notes that pooling samples taken every 15-30 minutes reduces the effect of a single pulse.

Sources: [1] [4]

What is primary ovarian insufficiency?

Premature loss of ovarian function, which raises FSH. A 2024 international guideline gives 145 recommendations on its diagnosis and treatment.

Sources: [11]

How much does FSH vary between tests?

Less than LH: within-person variation was about 8% for FSH and 26% for LH in men.

Sources: [57]

References

  1. Labcorp. Test 004309: Follicle-stimulating Hormone (FSH). Use, special instructions, limitations, additional information, specimen requirements, reference range and LOINC map. labcorp.com/tests/004309/follicle-stimulating-hormone-fsh
  2. Santi D, Crépieux P, Reiter E, et al. Follicle-stimulating Hormone (FSH) Action on Spermatogenesis: A Focus on Physiological and Therapeutic Roles. J Clin Med. 2020;9(4). PMID 32260182
  3. Schally AV, Arimura A, Kastin AJ, et al. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science. 1971;173(4001):1036-8. PMID 4938639
  4. Booth RA, Weltman JY, Yankov VI, et al. Mode of pulsatile follicle-stimulating hormone secretion in gonadal hormone-sufficient and -deficient women--a clinical research center study. J Clin Endocrinol Metab. 1996;81(9):3208-14. PMID 8784071
  5. Butler L, Santoro N. The reproductive endocrinology of the menopausal transition. Steroids. 2011;76(7):627-35. PMID 21419147
  6. Quest Diagnostics. Test code 470: FSH (Follicle Stimulating Hormone). Test directory entry (East region): methodology, clinical significance, reference ranges and LOINC. testdirectory.questdiagnostics.com/test/test-detail/470/fsh-follicle-stimulating-hormone?cc=PHP
  7. Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114(6):1151-1157. PMID 33280722
  8. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387-95. PMID 22343510
  9. Soules MR, Sherman S, Parrott E, et al. Stages of Reproductive Aging Workshop (STRAW). J Womens Health Gend Based Med. 2001;10(9):843-8. PMID 11747678
  10. Nieschlag E. Klinefelter syndrome: the commonest form of hypogonadism, but often overlooked or untreated. Dtsch Arztebl Int. 2013;110(20):347-53. PMID 23825486
  11. Panay N, Anderson RA, Bennie A, et al. Evidence-based guideline: premature ovarian insufficiency. Hum Reprod Open. 2024;2024(4):hoae065. PMID 39660328
  12. Anderson RE, Cragun JM, Chang RJ, et al. A pharmacodynamic comparison of human urinary follicle-stimulating hormone and human menopausal gonadotropin in normal women and polycystic ovary syndrome. Fertil Steril. 1989;52(2):216-20. PMID 2502437
  13. Jayasena CN, Nijher GM, Comninos AN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab. 2011;96(12):E1963-72. PMID 21976724
  14. Yeung AC, Phylactou M, Koysombat K, et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol. 2026;195(2):206-216. PMID 42549827
  15. Kallmann Syndrome. In: StatPearls [Internet]. StatPearls Publishing; 2024. PMID 30855798
  16. Hemrika DJ, Slaats EH, Kennedy JC, et al. Pulsatile luteinizing hormone patterns in long term oral contraceptive users. J Clin Endocrinol Metab. 1993;77(2):420-6. PMID 8345046
  17. LUPRON DEPOT (leuprolide acetate for depot suspension), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbc8f94e-7330-4465-05ad-16d64493a5dd
  18. Hu Y, Song X, Hamiti S, et al. Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis. BMC Endocr Disord. 2023;23(1):250. PMID 37974132
  19. Ye ZR, Yan CQ, Liao N, et al. The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials. Reprod Sci. 2023;30(8):2349-2361. PMID 37002532
  20. La Vignera S, Cannarella R, Garofalo V, et al. Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study. Reprod Biol Endocrinol. 2025;23(1):92. PMID 40604795
  21. Huhtaniemi I, Nikula H, Rannikko S. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels. J Androl. 1987;8(6):355-62. PMID 3123445
  22. Kluge M, Schüssler P, Schmidt D, et al. Ghrelin suppresses secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in women. J Clin Endocrinol Metab. 2012;97(3):E448-51. PMID 22259063
  23. Zhang Y, Qu Z, Lu T, et al. Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial. Nutrients. 2023;15(3). PMID 36771262
  24. Carey DG, Iismaa TP, Ho KY, et al. Potent effects of human galanin in man: growth hormone secretion and vagal blockade. J Clin Endocrinol Metab. 1993;77(1):90-3. PMID 7686918
  25. Giustina A, Gastaldi C, Bugari G, et al. Role of galanin in the regulation of somatotrope and gonadotrope function in young ovulatory women. Metabolism. 1995;44(8):1028-32. PMID 7543651
  26. Zucker I, Rainer Q, Pai RK, et al. Efficacy and Safety of Human Chorionic Gonadotropin Monotherapy for Men With Hypogonadal Symptoms and Normal Testosterone. Cureus. 2022;14(5):e25543. PMID 35800844
  27. Waśko R, Ruchała M, Sawicka J, et al. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly. J Endocrinol Invest. 2000;23(1):12-8. PMID 10698045
  28. Urwyler SA, Lustenberger S, Drummond JR, et al. Effects of oral macimorelin on copeptin and anterior pituitary hormones in healthy volunteers. Pituitary. 2021;24(4):555-563. PMID 33615399
  29. Watanobe H, Nigawara T, Anzai J, et al. Neuropeptide Y potentiates the luteinizing hormone (LH) response to LH-releasing hormone in men. Biochem Biophys Res Commun. 1994;200(2):1111-7. PMID 8179590
  30. Prelević GM, Wurzburger MI, Balint-Perić L. The effect of somatostatin analog octreotide (Sandostatin) on luteinizing hormone and ovarian steroids in insulin-dependent diabetic women without residual insulin secretion. Gynecol Endocrinol. 1992;6(4):259-63. PMID 1492581
  31. Chiodera P, Volpi R, d'Amato L, et al. Inhibition by somatostatin of LH-RH-induced LH release in normal menstruating women. Gynecol Obstet Invest. 1986;22(1):17-21. PMID 2875017
  32. Fischer UG, Wood SH, Bruhn J, et al. Effect of human corticotropin-releasing hormone on gonadotropin secretion in cycling and postmenopausal women. Fertil Steril. 1992;58(6):1108-12. PMID 1459256
  33. Olster DH, Ferin M. Corticotropin-releasing hormone inhibits gonadotropin secretion in the ovariectomized rhesus monkey. J Clin Endocrinol Metab. 1987;65(2):262-7. PMID 3110201
  34. Liu Z, Mao J, Wu X, et al. [Effectiveness and safety of pulsatile GnRH pump therapy on female patients with IHH]. Zhonghua Yi Xue Za Zhi. 2015;95(42):3432-5. PMID 26813133
  35. Gelander L, Lindstedt G, Selstam G, et al. Effects of acute intravenous injection of two growth hormone-releasing hormones (GHRH 1-40 and 1-29) on serum growth hormone and other pituitary hormones in short children with pulsatile growth hormone secretion. Horm Res. 1989;31(5-6):213-20. PMID 2515143
  36. Looij BJ, Nieuwenhuijzen Kruseman AC, Mudde AH, et al. The interaction of growth hormone releasing hormone with other hypothalamic hormones on the release of anterior pituitary hormones. Clin Endocrinol (Oxf). 1986;24(2):149-56. PMID 2871949
  37. Bremner WJ, de Kretser DM, Burger HG. Increases in serum concentrations of follicle-stimulating hormone (FSH) during thyrotrophin-releasing hormone (TRH) infusions in normal men. Clin Endocrinol (Oxf). 1977;7(5):339-404. PMID 412626
  38. Colon JM, Lessing JB, Yavetz C, et al. The effect of thyrotropin-releasing hormone stimulation on serum levels of gonadotropins in women during the follicular and luteal phases of the menstrual cycle. Fertil Steril. 1988;49(5):809-12. PMID 3129315
  39. Lee SG, Lundy LE, Kashef M, et al. Influence of thyrotropin-releasing hormone on the postmenopausal female. Obstet Gynecol. 1975;45(1):25-6. PMID 803307
  40. FIRMAGON (degarelix) for injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab11dd8a-0fd9-4013-89ab-e114557c7e4b
  41. Ganirelix Acetate Injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32fb74ff-993a-49fe-8943-e029372b863e
  42. ZOLADEX (goserelin implant), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3
  43. SYNAREL (nafarelin acetate) nasal spray, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6
  44. Letassy NA, Thompson DF, Britton ML, et al. Nafarelin acetate: a gonadotropin-releasing hormone agonist for the treatment of endometriosis. DICP. 1990;24(12):1204-9. PMID 2151003
  45. TRELSTAR (triptorelin pamoate for injectable suspension), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1b84d62-a369-a4b7-5c41-dd1f553a18f3
  46. TRIPTODUR (triptorelin) for extended-release injectable suspension, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f41380e7-b830-432d-a5f5-a872932f107e
  47. CETROTIDE (cetrorelix acetate for injection), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79
  48. Shokrollahi B, Zandi MIK, Palani A, et al. EFFECTS OF IRISIN ON REPRODUCTIVE HORMONES, LIPID PROFILES, AND OXIDATIVE STRESS BIOMARKERS IN MALE RATS. Acta Endocrinol (Buchar). 2025;21(1):37-46. PMID 41798973
  49. Shokrollahi B, Sharifi F. Dose- and time-dependent effects of intravenous irisin administration on GnRH, LH, FSH, and estrogen in Kurdish ewes during the breeding season. Res Vet Sci. 2025;193:105737. PMID 40505589
  50. Ozturk Öztürk DA, Erden Y, Tekin S. Central MOTS-c infusion affects reproductive hormones in obese and non-obese rats. Neurosci Lett. 2024;826:137722. PMID 38462167
  51. Eraslan E, Tanyeli A, Güler MC, et al. Neuroendocrine effects of exogenous adropin administration on the hypothalamic pituitary testicular axis in male rats. Turk J Med Sci. 2026;56(1):302-314. PMID 41816746
  52. Steele MK, Negro-Vilar A, McCann SM. Effect of central injection of bradykinin and bradykinin potentiating factor upon release of anterior pituitary hormones in ovariectomized female rats. Peptides. 1980;1(3):201-5. PMID 6785730
  53. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID 9849822
  54. Szlis M, Wójcik-Gładysz A, Przybył BJ. Central obestatin administration affect the LH and FSH secretory activity in peripubertal sheep. Theriogenology. 2020;145:10-17. PMID 31982689
  55. Vijayan E, Samson WK, McCann SM. Effects of arginine vasotocin on levels of plasma gonadotropins and prolactin in ovariectomized conscious rats. Proc Soc Exp Biol Med. 1983;173(1):153-8. PMID 6407023
  56. LOINC 15067-2: Follitropin [Units/volume] in Serum or Plasma. Regenstrief Institute. Record checked through the NLM Clinical Table Search Service. loinc.org/15067-2
  57. Røys EÅ, Guldhaug NA, Viste K, et al. Sex Hormones and Adrenal Steroids: Biological Variation Estimated Using Direct and Indirect Methods. Clin Chem. 2023;69(1):100-109. PMID 36373220
  58. Li CH, Simpson ME, Evans HM. Isolation of Pituitary Follicle-Stimulating Hormone (FSH). Science. 1949;109(2835):445-6. PMID 17821109

Educational information, not medical advice. Lab ranges and test codes were checked on October 30, 2026. Always use the range printed on your own report, and talk to a clinician about your results.